Locally Aggressive Fibromatosis | Beta-Catenin Driven | High Recurrence | Non-Metastasising
ANATOMIC CLASSIFICATION
Critical Must-Knows
- Sporadic desmoid harbours CTNNB1 exon 3 mutations driving nuclear beta-catenin accumulation
- Infiltrative growth along fascial planes without capsule; no metastatic potential but local destruction
- MRI shows T2-hyperintense bands with tail sign; biopsy confirms spindle cells with beta-catenin IHC
- Watchful waiting is first-line for most asymptomatic extra-abdominal lesions; progression occurs in 30-50 percent
- Surgery aims for R0 margins but recurrence remains 20-50 percent; function-preserving approaches preferred
Clinical Pearls
- "Desmoid = aggressive fibromatosis; never call it low-grade fibrosarcoma
- "Beta-catenin and APC pathway link sporadic and FAP-associated disease
- "MRI tail sign and band-like T2 hyperintensity are characteristic
- "Surgery is no longer automatic first-line; systemic options have changed practice
Critical Desmoid Tumour Decision Points
Biology First
CTNNB1 mutation drives 85-90 percent sporadic desmoids. Nuclear beta-catenin on IHC supports diagnosis. APC germline mutation defines FAP-associated cases. Always obtain family history.
Natural History
30-50 percent progress; 20-30 percent stable; 10-20 percent regress spontaneously. Document growth rate with serial MRI before active treatment. Asymptomatic limb lesions often observed.
MRI Diagnosis
T2 hyperintense bands and tail sign along fascia. Infiltrative margins without capsule. Biopsy before any treatment. Core needle preferred; avoid excisional biopsy.
Treatment Shift
Watchful waiting first for most extra-abdominal cases. Surgery reserved for progression causing pain, compression or functional loss. Systemic therapy (sorafenib, pazopanib, chemo) increasingly used.
Quick Decision Guide
| Presentation | Key Feature | Initial Approach | Key Pearl |
|---|---|---|---|
| Asymptomatic extra-abdominal mass | Stable on serial MRI, minimal symptoms | Watchful waiting with MRI every 3-6 months | 50 percent remain stable or regress |
| Symptomatic or growing lesion | Pain, compression, functional deficit | Systemic therapy or function-preserving surgery | R0 margins difficult; recurrence 20-50 percent |
| FAP-associated mesenteric desmoid | Multifocal, bowel involvement risk | Multidisciplinary; avoid aggressive resection | Mortality from desmoid in FAP is significant |
WNT-ONBeta-Catenin Pathway in Desmoid
| W | Wnt ligand binding Activates canonical pathway |
| N | Nuclear translocation Mutated beta-catenin enters nucleus |
| T | TCF/LEF transcription Drives cyclin D1, c-Myc, proliferation |
| O | Oncogenic driver CTNNB1 exon 3 mutation in 85-90 percent |
| N | No metastasis Locally aggressive only; no distant spread |
| W | Wnt ligand binding Activates canonical pathway | O | Oncogenic driver CTNNB1 exon 3 mutation in 85-90 percent |
| N | Nuclear translocation Mutated beta-catenin enters nucleus | N | No metastasis Locally aggressive only; no distant spread |
| T | TCF/LEF transcription Drives cyclin D1, c-Myc, proliferation |
Hook:WNT-ON explains why desmoid grows locally but never metastasises!
BANDSMRI Features of Desmoid
| B | Band-like T2 hyperintensity Characteristic fascial infiltration |
| A | Aggressive margins Infiltrative without capsule |
| N | No enhancement pattern Variable gadolinium uptake |
| D | Deep fascial tail sign Extension along fascia on T2 |
| S | Size and stability Serial imaging critical for decision |
| B | Band-like T2 hyperintensity Characteristic fascial infiltration | D | Deep fascial tail sign Extension along fascia on T2 |
| A | Aggressive margins Infiltrative without capsule | S | Size and stability Serial imaging critical for decision |
| N | No enhancement pattern Variable gadolinium uptake |
Hook:BANDS on MRI = think desmoid before biopsy!
WATCH-SURGERYTreatment Escalation Ladder
| W | Watchful waiting First line for stable asymptomatic |
| A | Anti-oestrogen / NSAID Tamoxifen + sulindac historical option |
| T | TKI therapy Sorafenib or pazopanib for progressing |
| C | Chemotherapy Methotrexate-vinblastine or doxorubicin |
| H | High-dose or radiation Selected cases only |
| S | Surgery Function-preserving when systemic fails |
| W | Watchful waiting First line for stable asymptomatic | T | TKI therapy Sorafenib or pazopanib for progressing | H | High-dose or radiation Selected cases only |
| A | Anti-oestrogen / NSAID Tamoxifen + sulindac historical option | C | Chemotherapy Methotrexate-vinblastine or doxorubicin | S | Surgery Function-preserving when systemic fails |
Hook:WATCH first, SURGERY last for most desmoids!
Overview and Epidemiology
Why This Matters
Desmoid tumours (aggressive fibromatosis) are rare fibroblastic neoplasms that exhibit locally infiltrative growth without metastatic capacity. They arise from mesenchymal stem cells and are driven by dysregulation of the Wnt/beta-catenin pathway. In orthopaedic practice they most commonly present as extra-abdominal masses in the shoulder girdle, chest wall, thigh or forearm. Although benign in metastatic terms, their infiltrative behaviour causes pain, deformity, joint contracture and functional loss. Modern management has shifted dramatically from aggressive surgery toward observation and systemic therapies because recurrence after resection remains 20-50 percent even with negative margins.
Epidemiology
- Incidence: 2-4 per million per year worldwide
- Age peak: 15-40 years; female predominance in abdominal wall type
- Sporadic: 85-90 percent; CTNNB1 mutation positive
- FAP-associated: 5-10 percent; APC germline mutation; intra-abdominal predominance
- Extra-abdominal: 60-70 percent of orthopaedic presentations
Clinical Impact
- Local destruction: Infiltrates muscle, fascia, neurovascular structures
- Recurrence: 20-50 percent after surgery; higher with positive margins
- Functional loss: Joint contracture, nerve compression, deformity
- Mortality: Rare but occurs in FAP mesenteric disease from bowel obstruction
- Quality of life: Chronic pain and repeated interventions common
Pathophysiology
Wnt/Beta-Catenin Signalling in Desmoid
Sporadic desmoid tumours harbour somatic mutations in CTNNB1 (beta-catenin gene) exon 3 in 85-90 percent of cases. These mutations prevent phosphorylation and degradation of beta-catenin, leading to its nuclear accumulation. Nuclear beta-catenin binds TCF/LEF transcription factors and constitutively activates target genes including cyclin D1, c-Myc and matrix metalloproteinases. The result is uncontrolled fibroblastic proliferation along fascial planes. In FAP, germline APC mutations remove the negative regulator of beta-catenin, producing the same pathway activation. No capsule forms; tumour infiltrates surrounding tissues, explaining the high local recurrence rate despite non-metastasising behaviour.
Sporadic versus FAP-Associated Desmoid
| Feature | Sporadic | FAP-Associated |
|---|---|---|
| Mutation | Somatic CTNNB1 exon 3 (85-90 percent) | Germline APC + somatic second hit |
| Location | Extra-abdominal (limb, trunk wall) | Intra-abdominal (mesentery) predominant |
| Multifocality | Rare (less than 5 percent) | Common (up to 30 percent) |
| Recurrence risk | 20-50 percent after surgery | Higher; field cancerisation effect |
Infiltrative Growth Pattern
No capsule. Tumour extends along fascial planes, between muscle fibres and around neurovascular bundles. This explains why wide margins are difficult to achieve without major functional sacrifice and why microscopic disease remains after resection.
Why No Metastasis
Although locally aggressive, desmoid cells lack the additional genetic hits required for haematogenous or lymphatic spread. They remain dependent on local microenvironment and Wnt signalling; distant implantation does not occur.
Classification and Types
Classification by Location
| Type | Common Sites | Orthopaedic Relevance | Special Considerations |
|---|---|---|---|
| Extra-abdominal | Shoulder, chest wall, thigh, forearm, head-neck | Most common in orthopaedic clinics | Function-preserving strategies critical |
| Abdominal wall | Rectus abdominis, post-partum | Less limb involvement | Often resectable with mesh reconstruction |
| Intra-abdominal | Mesentery, retroperitoneum | FAP screening context | Bowel involvement; high morbidity |
Clinical Assessment
History
- Pain: Dull, activity-related or night pain from mass effect
- Growth: Patient or family notice enlarging mass over months
- Function: Joint stiffness, weakness, paraesthesia if nerve involved
- Family history: Polyposis, previous desmoid, thyroid cancer (FAP)
- Prior surgery or trauma: 10-20 percent report antecedent event
Examination
- Palpation: Firm, fixed to deep fascia, non-tender unless inflamed
- Margins: Poorly defined; extends along fascial planes
- Neurovascular: Assess for compression (common in axilla, popliteal fossa)
- Joint ROM: Contracture or reduced motion from infiltration
- Skin: Usually intact; rarely ulcerated
Red Flags Requiring Urgent Investigation
Any deep fascial or intramuscular mass greater than 5 cm with infiltrative margins on imaging requires biopsy. Do not observe presumed lipoma or haematoma without MRI. In young adults with shoulder or thigh mass, desmoid is in the differential alongside sarcoma.
Differential Diagnosis of Deep Fascial Mass
| Condition | Distinguishing Feature | Key Investigation | Management Difference |
|---|---|---|---|
| Desmoid tumour | Infiltrative, beta-catenin positive | MRI + core biopsy + IHC | Observation or systemic first |
| Soft-tissue sarcoma | More circumscribed, heterogeneous | MRI + biopsy (molecular) | Wide resection primary |
| Fibroma of tendon sheath | Small, superficial, tendon-related | Ultrasound + excision | Marginal excision curative |
| Nodular fasciitis | Rapid growth, self-limiting | Biopsy shows myofibroblasts | Observation or excision |
Investigations
Diagnostic Algorithm
Protocol: T1, T2, STIR, post-contrast sequences of entire compartment Characteristic findings: T2-hyperintense band-like areas, tail sign along fascia, infiltrative margins, variable enhancement Clinical correlation: Size, growth rate on serial scans, relationship to neurovascular structures and joints
Technique: Image-guided (ultrasound or CT) 14-16G cores; minimum 4-6 cores Histology: Bland spindle cells in collagenous stroma; no atypia or mitoses IHC: Nuclear beta-catenin (70-90 percent sensitivity); vimentin positive; SMA variable Molecular: CTNNB1 sequencing if IHC equivocal or wild-type
CT chest: Rule out metastasis (rare but performed for completeness) Colonoscopy / genetic testing: If wild-type CTNNB1 or family history suggestive of FAP PET-CT: Selected cases for aggressive or multifocal disease
Biopsy Pearl
Never perform excisional biopsy of a suspected desmoid. The infiltrative nature means positive margins are inevitable and subsequent re-excision is more morbid. Core needle biopsy provides definitive diagnosis while preserving options for observation or systemic therapy.
Management Algorithm
Watchful Waiting (First-Line for Most Extra-Abdominal Cases)
Indication: Asymptomatic or minimally symptomatic, stable or slowly growing on serial MRI, no neurovascular compromise or joint contracture.
Observation Protocol
Full MRI of compartment plus clinical photography and functional scores
MRI every 3 months; clinical review monthly. Document growth velocity.
If stable, extend interval to 6 months. Many lesions stabilise or regress.
Annual MRI if no progression. Counsel on lifetime recurrence risk even after stability.
Approximately 50 percent of extra-abdominal desmoids remain stable or regress with observation alone.
Complications
| Complication | Incidence | Risk Factors | Management |
|---|---|---|---|
| Local recurrence | 20-50 percent after surgery | Positive margins, S45F mutation, young age | Re-operation or systemic therapy |
| Joint contracture | 15-30 percent untreated or post-op | Shoulder, elbow, knee involvement | Physiotherapy, serial splinting, surgery |
| Neurovascular injury | 5-15 percent at presentation or surgery | Axillary, popliteal, forearm locations | Nerve decompression or grafting |
| Wound complications | 10-20 percent after resection | Large defects, prior radiation | Flap coverage, negative-pressure therapy |
| Mesenteric desmoid mortality (FAP) | Up to 10-15 percent of FAP desmoids | Bowel obstruction, perforation | Multidisciplinary intestinal transplant centre |
Recurrence Prevention Strategy
The single most effective way to reduce recurrence is to avoid surgery in stable, asymptomatic lesions. When surgery is required, counsel patients that microscopic disease almost always remains and that systemic therapy or re-observation is often needed later. Document mutation status (S45F carries higher risk).
Outcomes and Prognosis
Outcomes by Treatment Strategy
| Strategy | Local Control | Function | Long-Term Notes |
|---|---|---|---|
| Watchful waiting | 50-70 percent stable at 5 years | Preserved in majority | Best functional outcome when successful |
| Systemic therapy first | 30-50 percent response; many stable | Good preservation | Surgery avoided or delayed in 60-70 percent |
| Surgery alone | 50-80 percent R0; 20-50 percent recur | Variable; depends on margins | Function loss common with wide resection |
| Multimodal (FAP mesenteric) | Variable; high morbidity | Often compromised | Survival improved with modern agents |
Prognostic Factors
Favourable: Asymptomatic at presentation, stable on observation, extra-abdominal location, wild-type or T41A mutation. Unfavourable: S45F mutation, young age less than 30, positive margins at surgery, FAP-associated intra-abdominal disease, rapid growth greater than 20 percent in 3 months. Key threshold: Document growth rate on two consecutive MRI scans before declaring progression and escalating therapy.
Evidence Base and Key Trials
Beta-catenin mutations in desmoid-type fibromatosis
- CTNNB1 exon 3 mutations identified in 85 percent of sporadic desmoid tumours
- S45F mutation associated with higher recurrence risk after surgery
- Nuclear beta-catenin IHC correlates strongly with mutation status
- APC mutations confirmed in all FAP-associated cases tested
Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment
- Front-line conservative (non-operative) approach evaluated in extra-abdominal desmoid fibromatosis
- Patients selected for observation based on symptoms and tumour behaviour rather than routine surgery
- Only a subset required surgical intervention after initial surveillance period
- Function preserved in majority of patients managed conservatively
Sorafenib for advanced desmoid tumours
- Randomised placebo-controlled trial of sorafenib in 87 progressing desmoids
- Two-year progression-free survival 81 percent versus 36 percent placebo
- Partial response in 33 percent of sorafenib arm
- Manageable toxicity profile; hand-foot syndrome most common
Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution
- Single-institution series of patients with extra-abdominal aggressive fibromatosis treated surgically
- Quality of surgical margins significantly influenced local recurrence rate
- Wide margins achieved lower recurrence but at cost of greater functional morbidity
- Substantial recurrence even with negative margins, questioning routine aggressive surgery
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ)
- Randomised phase 2 trial comparing pazopanib versus methotrexate-vinblastine in progressive desmoid tumours
- Both treatments showed clinical activity with manageable toxicity profiles
- Pazopanib arm demonstrated favourable progression-free survival
- Provides prospective evidence for TKI therapy as systemic option in progressing disease
Exam Viva Scenarios
Use these scenarios to practise clinical reasoning and management decisions
Scenario 1: Asymptomatic Extra-Abdominal Mass
"A 32-year-old woman presents with a 6 cm firm mass in the deltoid region noticed incidentally. MRI demonstrates an infiltrative T2-hyperintense lesion along the deltoid fascia with tail sign and no neurovascular encasement. Core biopsy confirms desmoid tumour with nuclear beta-catenin positivity and CTNNB1 T41A mutation. She has no pain or functional deficit. What is your management?"
Scenario 2: Progressive FAP-Associated Mesenteric Desmoid
"A 28-year-old man with known FAP status post-colectomy presents with a 12 cm mesenteric desmoid causing intermittent bowel obstruction and 15 kg weight loss. Previous attempts at resection have failed. CT shows multifocal disease with superior mesenteric artery encasement. What is your management plan?"
MCQ Practice Points
Mutation Question
Q: What is the most common mutation in sporadic desmoid tumours and its clinical relevance? A: CTNNB1 exon 3 mutation (T41A or S45F) in 85-90 percent. Nuclear beta-catenin IHC is positive. S45F subtype carries higher post-operative recurrence risk and may prompt earlier systemic therapy consideration. Wild-type cases require APC germline testing for FAP.
Imaging Question
Q: What are the characteristic MRI features of desmoid tumour? A: T2-hyperintense band-like areas, tail sign along fascia, infiltrative non-encapsulated margins, variable enhancement. These features in a young adult with shoulder or thigh mass should prompt core biopsy before any treatment. Serial MRI documents growth velocity for treatment decisions.
Management Question
Q: What is the current first-line treatment for an asymptomatic extra-abdominal desmoid? A: Watchful waiting with serial MRI. Approximately 50 percent remain stable or regress. Active treatment (systemic therapy or surgery) is reserved for documented progression, pain, compression or functional loss. This approach preserves function and avoids unnecessary recurrence risk from surgery.
Systemic Therapy Question
Q: Which systemic agent has level-1 evidence in progressing desmoid tumours? A: Sorafenib. Randomised trial showed 81 percent 2-year progression-free survival versus 36 percent placebo. Partial responses in one-third. Pazopanib is an alternative TKI. Low-dose chemotherapy regimens remain options in selected patients.
FAP Question
Q: How does management of FAP-associated mesenteric desmoid differ from sporadic extra-abdominal disease? A: Higher mortality risk from bowel obstruction; surgery avoided when possible due to field cancerisation and vascular involvement. Systemic therapy is mainstay. Multidisciplinary care in specialist centres; genetic counselling mandatory. Observation still used for stable lesions but progression threshold for intervention is lower.
Guidelines, Registries & Global Practice
Global Epidemiology
- Incidence 2-4 per million annually across all populations
- Extra-abdominal locations predominate in orthopaedic practice worldwide
- FAP-associated proportion higher in populations with established polyposis registries
- Female predominance in abdominal wall desmoids (post-partum) universal
Practice Variation
- High-resource centres: routine CTNNB1 sequencing, sorafenib access, dedicated sarcoma MDT
- Resource-limited: observation with basic MRI, tamoxifen-sulindac still used, surgery when systemic unavailable
- Universal principle: function preservation and avoidance of unnecessary surgery now accepted globally
Society Guidance Summary
| Source | First-Line Approach | Surgery Indication | Systemic Therapy |
|---|---|---|---|
| NCCN (US) | Observation for asymptomatic | Progression or symptoms only | Sorafenib preferred; pazopanib alternative |
| ESMO (Europe) | Watchful waiting preferred | Function-threatening progression | TKI or low-dose chemotherapy options |
| BCCA / UK guidelines | Observation first; MDT review | After systemic failure | Access to sorafenib via specialist centres |
Registry Note
No international desmoid-specific registry exists comparable to bone tumour registries. Data derive from institutional series and the few randomised trials (sorafenib). Global collaboration through sarcoma networks is increasing. Document mutation status, growth kinetics and functional scores in every case to contribute to future evidence.
Controversies & Areas of Uncertainty
Optimal surveillance interval
No consensus on exact MRI timing after stability. Most centres use 3-monthly initially then 6-monthly, but evidence is limited. Over-imaging versus missed progression remains a trade-off.
Role of adjuvant radiotherapy
Radiotherapy after R1 resection reduces recurrence in some series but causes fibrosis and secondary malignancy risk. Modern practice favours systemic therapy over radiation for most extra-abdominal cases.
S45F mutation and surgical decision
Higher recurrence risk is established, yet many S45F tumours remain stable. Whether mutation alone should trigger surgery or systemic therapy in asymptomatic patients is unresolved.
Pregnancy-associated desmoid
Abdominal wall desmoids may enlarge during pregnancy. Management during gestation, delivery mode and post-partum observation versus intervention lack high-quality data.
DESMOID TUMOUR (AGGRESSIVE FIBROMATOSIS)
Clinical summary
Key Biology
- •CTNNB1 exon 3 mutation (T41A or S45F) in 85-90 percent sporadic cases
- •Nuclear beta-catenin drives Wnt pathway; no metastatic potential
- •FAP-associated via germline APC; intra-abdominal predominance
- •S45F mutation carries higher post-operative recurrence risk
Diagnosis
- •MRI: T2 band-like hyperintensity, tail sign, infiltrative margins
- •Core biopsy mandatory; never excisional biopsy
- •IHC: nuclear beta-catenin; molecular confirmation if needed
- •Screen for FAP if CTNNB1 wild-type or family history
Management Algorithm
- •Watchful waiting first-line for asymptomatic extra-abdominal stable lesions
- •Define progression on two serial MRI scans before escalating
- •Sorafenib first systemic option; pazopanib or chemo alternatives
- •Surgery only for progression after systemic therapy or critical threat
Recurrence & Prognosis
- •Recurrence 20-50 percent after surgery even with R0 margins
- •50 percent of observed lesions remain stable or regress
- •Function preservation is primary goal; avoid unnecessary surgery
- •FAP mesenteric disease carries 10-15 percent mortality risk
Exam Pearls
- •Never call desmoid low-grade fibrosarcoma; it never metastasises
- •Watchful waiting is now evidence-based first-line therapy
- •Document mutation subtype; S45F influences counselling
- •Multidisciplinary care mandatory for FAP-associated cases